Ribatti D. Immunosuppressive effects of vascular endothelial growth factor[J]. Oncol Lett, 2022, 24(4): 369.

Wang ZY, Liu WL, Zhao ZQ. Mechanism by which vascular endothelial growth factor A targets regulation of angiogenesis in the treatment of steroid-induced osteonecrosis of the femoral head[J]. Zhongguo Zu Zhi Gong Cheng Yan Jiu, 2025, 30(3): 671-679.

Muratori L, Gnavi S, Fregnan F, et al . Evaluation of Vascular Endothelial Growth Factor (VEGF) and Its Family Member Expression After Peripheral Nerve Regeneration and Denervation[J ] . Anat Rec (Hoboken), 2018, 301(10): 1646-1656.

Kurtagic E, Rich CB, Buczek-Thomas JA, et al . Neutrophil Elastase-Generated Fragment of Vascular Endothelial Growth Factor-A Stimulates Macrophage and Endothelial Progenitor Cell Migration[J ] . PLoS One, 2015, 10(12): e0145115.

Qiu LP, Sun ZY, Zhao X, et al. Research advances in mechanism and clinical application of anti-angiogenesis therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer[J]. Jiefangjun Yi Xue Yuan Xue Bao, 2022, 43(12): 1288-1292, 1297.

Wang J, Yan YD, Tang H, et al. Mechanism and treatment of proteinuria induced by anti-tumor angiogenesis drugs[J]. Shi Jie Lin Chuang Yao Wu, 2023, 44(4): 375-378.

Li JP, Lu ZC, Zhang GZ, et al. The efficacy and safety of bevacizumab combined with radiotherapy in the treatment of elderly brain metastases[J]. Zhongguo Lao Nian Xue Za Zhi, 2023, 43(19): 4646-4649.

Massey PR, Okman JS, Wilkerson J, et al . Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature[J ] . Support Care Cancer, 2015, 23(6): 1827-1835.

Qian QQ, Li GZ, Tian H, et al. Design, preparation, and antitumor activity of fusion protein vaccine based on tumor antigen PBK[J]. Zhongguo Yao Ke Da Xue Xue Bao, 2024, 55(5): 657-665.

Zhang LL. Effect of Iguratimod Combined with Recombinant Human Type Ⅱ Tumor Necrosis Factor Receptor-antibody Fusion Protein in the Treatment of Rheumatoid Arthritis and the Influence on Disease Activity and Inflammatory Factors[J]. Zhongguo Yi Xue Chuang Xin, 2022, 19(3): 23-26.

Liu F, Hidru TH, Gao R, et al . Cancer patients with potential eligibility for vascular endothelial growth factor antagonists use have an increased risk for cardiovascular diseases comorbidities[J ] . J Hypertens, 2020, 38(3): 426-433.

Milan A, Puglisi E, Ferrari L, et al . Arterial hypertension and cancer[J ] . Int J Cancer, 2014, 134(10): 2269-2277.

Garcia J, Hurwitz HI, Sandler AB, et al . Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook[J ] . Cancer Treat Rev, 2020, 86: 102017.

Ma XL, Cao LY, Wang X, et al. Efficacy and safety of ramucircumab in treatment of advanced non-small cell lung cancer: a Meta analysis[J]. Zhongguo Zhong Liu Sheng Wu Zhi Liao Za Zhi, 2018, 25(5): 515-521.

Yang T, Wang GJ, Feng BM, et al. Efficacy and Safety of Ramucirumab in the Treatment of Adenocarcinoma in Stomach or Gastroesophageal Junction: A Meta-analysis[J]. Zhongguo Yao Fang, 2016, 27(6): 789-792.

Deng Z, Xiao S, He YY, et al . Sorafenib-induced cardiovascular toxicity: A cause for concern[J ] . Chem Biol Interact, 2025, 410: 111388.

Shen G, Zheng F, Ren D, et al . Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development[J ] . J Hematol Oncol, 2018, 11(1): 120.

Wang Z, Zou JJ, Li Z, et al. Targeted Drugs in Colorectal Cancer[J]. Zhongguo Yao Xue Za Zhi, 2016, 51(24): 2077-2081.

Dobbin SJH, Cameron AC, Petrie MC, et al . Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors[J ] . Heart, 2018, 104(24): 1995-2002.

Rizzoni D, De Ciuceis C, Porteri E, et al . Use of Antihypertensive Drugs in Neoplastic Patients[J ] . High Blood Press Cardiovasc Prev, 2017, 24(2): 127-132.

Freites-Martinez A, Santana N, Arias-Santiago S, et al . Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies[J ] . Actas Dermosifiliogr (Engl Ed), 2021, 112(1): 90-92.

Li BY, Guo DH, Kong XH, et al. Analysis of 972 spontaneous reports of adverse drug reactions induced by angiogenesis inhibitors[J]. Zhongguo Lin Chuang Yao Li Xue Za Zhi, 2021, 37(11): 1441-1443, 1450.

Wiszniak S, Schwarz Q. Exploring the Intracrine Functions of VEGF-A[J]. Biomolecules, 2021, 11(1): 128.

Luo YD, Ding RX, Bao YX, et al. Yindan xinnaotong capsule regulates AKT to inhibit neointimal hyperplasia: mechanism study based on network pharmacological analysis[J]. Zunyi Yi Ke Da Xue Xue Bao, 2024, 47(2): 127-134.

Kang M, Liu WH, Huang RB, et al. Clinical pharmacists participating in the treatment of grade-3 proteinuria induced by bevacizumab[J]. Shi Yong Yao Wu Yu Lin Chuang, 2019, 22(12): 1312-1315.

Peng Y, Zhang R. Pathogenesis, diagnosis and treatment of drug-induced thrombotic microangiopathy[J]. Zhongguo Shi Yong Nei Ke Za Zhi, 2023, 43(6): 457-460.

Yi H, Ruzetuoheti G, Jiang MY, et al. Efficacy and safety of bevacizumab combination with irinotecan/raltitrexed in patients with fluorouracil-refractory advanced colorectal cancer[J]. Yao Wu Ping Jia Yan Jiu, 2020, 43(2): 293-298.

Estrada CC, Maldonado A, Mallipattu SK. Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities[J]. J Am Soc Nephrol, 2019, 30(2): 187-200.

Klepin HD, Garrett-Mayer E, Kaltenbaugh M, et al . Hypertension and use of bevacizumab among patients treated in community settings[J ] . J Clin Oncol, 2019, 37(15_suppl): e18279.

Pang PJ, Yin X, Liu TY, et al. Signal Mining of Bevacizumab-Related Adverse Drug Events Based on FAERS[J]. Zhongguo Yao Ye, 2024, 33(14): 109-113.

Plummer C, Michael A, Shaikh G, et al . Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK[J ] . Br J Cancer, 2019, 121(2): 109-116.

Pan WJ, Pan Q, Luo XF. Study on Mechanism and Effect of Tianma Gouteng Yin(天麻钩藤饮) in Treatment of Mitochondrial Protein Pathway Regulated by Hypertension[J]. Zhonghua Zhong Yi Yao Xue Kan, 2025, 43(10): 41-44.

Xu HY, Zhang Y. Effects of Yangyin Quyu Formula on Serum VEGF and IFN-γ Levels and Immune Function in Patients with Pulmonary Tuberculosis[J]. Shi Jie Zhong Xi Yi Jie He Za Zhi, 2023, 18(1): 148-152.

Zeng SQ, Zhou FT. Clinical Effect Analysis of Modified Tianma Gouteng Drink in the Treatment of Patients with Liver Yang Hyperactivity Type Dizziness[J]. Xi Tong Yi Xue, 2025, 10(15): 183-185, 198.

Wang YT, Ma RF, Wu Y, et al. Analysis on influencing factors of Huachansu Injection intraperitoneal perfusion in treating colon cancer with malignant ascites[J]. Shanghai Zhong Yi Yao Da Xue Xue Bao, 2022, 36(3): 20-24.

Wang ZY, Tian DY, Zheng P, et al. Muscone improves coronary microvascular disease by promoting VEGF-mediated microvascular angiogenesis[J]. Lu Jun Jun Yi Da Xue Xue Bao, 2025, 47(19): 2374-2384.

Person F, Rinschen MM, Brix SR, et al . Bevacizumab-associated glomerular microangiopathy[J ] . Mod Pathol, 2019, 32(5): 684-700.

Gu X, Zhang S, Zhang T. Abnormal Crosstalk between Endothelial Cells and Podocytes Mediates Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity[J]. Cells, 2021, 10(4): 869.

Shye M, Hanna RM, Patel SS, et al . Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy[J ] . Clin Kidney J, 2020, 13(6): 969-980.

Gan G, Michel M, Max A, et al . Membranoproliferative glomerulonephritis after intravitreal vascular growth factor inhibitor injections: A case report and review of the literature[J ] . Br J Clin Pharmacol, 2023, 89(1): 401-409.

Kanbayashi Y, Ishikawa T, Tabuchi Y, et al . Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis[J ] . Scientific Reports, 2020, 10(1): 2011.

Nihei S, Asaka J, Yaegashi M, et al . Effect of blood pressure control on the risk of proteinuria during bevacizumab treatment in patients with colorectal cancer: a single-center retrospective cohort study[J ] . J Pharm Health Care Sci, 2024, 10(1): 51.

Dote S, Shiwaku E, Kohno E, et al . Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study[J ] . Int J Clin Oncol, 2023, 28(8): 1054-1062.

Kimura M, Usami E, Teramachi H, et al . Elucidation of optimal proteinuria management based on the risk of ramucirumab-induced proteinuria[J ] . Oncol Lett, 2022, 23(2): 45.

Kato T, Kurasawa S, Takezawa K, et al . Efficacy and Safety of Anti-angiogenic Agents for Cancer Patients With Proteinuria or a History of Proteinuria: A Systematic Review[J ] . Anticancer Res, 2024, 44(3): 889-894.

Xu LL, Zhou JX, Yang T, et al. Incidence and risk of proteinuria induced by anlotinib: a Meta-analysis[J]. Shi Yong Yao Wu Yu Lin Chuang, 2023, 26(3): 200-205.

Peng L, Zhao Q, Ye X, et al . Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis[J ] . PLoS One, 2014, 9(11): e111839.

Cosmai L, Gallieni M, Liguigli W, et al . Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs)[J ] . J Nephrol, 2017, 30(2): 171-180.

Pfister F, Amann K, Daniel C, et al . Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy[J ] . Histopathology, 2018, 73(6): 990-1001.

Member of the Chinese Expert Consensus Group on the Diagnosis and Treatment of Hypertensive Nephropathy. Chinese Expert Consensus on the Diagnosis and Treatment of Hypertensive Nephropathy[J]. Zhonghua Gao Xue Ya Za Zhi, 2022, 30(4): 307-317.

Ren Y, Wu ZC. Experience in Differential Treatment of Renal Proteinuria Based on the Theory of "Simultaneous Treatment of Spleen and Kidney"[J]. Ya Tai Chuan Tong Yi Yao, 2025, 21(10): 125-129.

Xiong Y, Du SC, Yang SM, et al. Based on the theory of "Yin and Yang are essential, and Yang Density is solid", to discusses the pathogenesis and treatment of proteinuria in Traditional Chinese Medicine[J]. Zhong Yi Xue, 2025, 14(1): 261-267.

Wang F, Yang XY, Sun C, et al. Clinical Characteristics of Stasis-Toxin Pathogenesis in Patients with Nonsmall Cell Lung Cancer of Blood Stasis and Qi Stagnation Syndrome and the Interventional Mechanism of Adjuvant Therapy with Bufei Huayu Decoction[J]. Guangzhou Zhong Yi Yao Da Xue Xue Bao, 2024, 41(1): 68-77.

Zhao YL, Wu ZL, Qian WN, et al. Analysis of the Effects of Fuzheng Yiqi Decoction Combined with Chemotherapy on Serum Levels of MMP-9, VEGF and T cell Subsets in Patients with Advanced Nonsmall Cell Lung Cancer[J]. Xian Dai Zhong Yao Yan Jiu Yu Shi Jian, 2017, 31(6): 68-71.

Wang LN, Liu SW. Observation on the Therapeutic Effect of Sijunzi Decoction Combined with modified Liuwei Dihuang Pills in the Treatment of Early Diabetic Nephropathy with Qi and Yin Deficiency Type[J]. Shi Yong Zhong Yi Yao Za Zhi, 2025, 41(6): 1229-1232.

Wang MM, Fang J, Luan XJ, et al. To explore the renal damage caused by Alisma orientalis and its renal protective mechanism in the combination of Liuwei Dihuang Pills from the perspective of "gut-kidney axis"[J]. Zhonghua Zhong Yi Yao Xue Kan, 2026, 44(1): 121-127, 268-271.

Zhao XY, Li LP, Zhan Q, et al. Yikunyin Activated Endoth elial Progenitor Cells via ERα-SDF-1/CXCR4 Axis to Repair Injured Vascular Endothelial Cells[J]. Zhong Yao Yao Li Yu Lin Chuang, 2026, 42(1): 27-36.

Fang LW, Ma HZ, Ding YY, et al. Mechanism of Astragalus extract in alleviating high glucose-induced podocyte injury via the VEGF/PI3K/AKT signaling pathway[J]. Zhejiang Zhong Xi Yi Jie He Za Zhi, 2025, 35(6): 514-518, 528.

Huang W, Wang JJ, Huang Y, et al. The effect of compound Kushen Injection combined with chemotherapy and bevacizumab onshort-term efficacy of patients with ovarian cancer[J]. Tianjin Yi Yao, 2026, 54(1): 88-92.

Yao X, Yang JJ. Sorafenib in the Treatment of Hepatocellular Carcinoma[J]. Lin Chuang Yi Xue Jin Zhan, 2020, 10(10): 2241-2245.

Rimassa L, Danesi R, Pressiani T, et al . Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma[J ] . Cancer Treat Rev, 2019, 77: 20-28.

Li J, Gu J. Hand-foot skin reaction with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2017, 119: 50-58.

Ding J, Farah MH, Nayfeh T, et al . Targeted Therapy- and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis[J ] . Oncol Nurs Forum, 2020, 47(5): e149-e160.

Luo P, Yan H, Chen X, et al . s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand-foot skin reaction that can be reversed by nicotinamide[J ] . Cell Res, 2020, 30(9): 779-793.

Zhang L, Zhou Q, Ma L, et al . Meta-analysis of dermatological toxicities associated with sorafenib[J ] . Clin Exp Dermatol, 2011, 36(4): 344-350.

Gomez P, Lacouture ME. Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer[J]. Oncologist, 2011, 16(11): 1508-1519.

McLellan B, Ciardiello F, Lacouture ME, et al . Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management[J ] . Ann Oncol, 2015, 26(10): 2017-2026.

Tovoli F, Ielasi L, Casadei-Gardini A, et al . Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients[J ] . J Hepatol, 2019, 71(6): 1175-1183.

Ochi M, Kamoshida T, Araki M, et al . Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment[J ] . World J Gastroenterol, 2021, 27(32): 5424-5437.

Ai L, Xu Z, Yang B, et al . Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management[J ] . Expert Rev Clin Pharmacol, 2019, 12(12): 1121-1127.

Zhang MF, Lu WP, Cui YJ, et al. Syndrome differentiation and treatment of hand-foot skin reaction in traditional Chinese medicine[J]. Jilin Zhong Yi Yao, 2024, 44(11): 1279-1283.

Zhao DH, Chu MM, Chen J, et al. Meta-analysis and GRADE profile of vitamin B6 for preventing hand-foot syndrome caused by capecitabine[J]. Shi Yong Yao Wu Yu Lin Chuang, 2018, 21(10): 1132-1136.

Zhang HQ, Wang ZH, Lyu YE. Treating one case of adult Steele's disease with SHI Jinmo's medicine-pair prescription[J]. Zhong Yi Lin Chuang Yan Jiu, 2022, 14(17): 116-117.

Mao YM, Hao LP, Guo HJ, et al. Research Progress on the Treatment of hand-foot Skin Reactions Related to Anti-angiogenic Drugs with External Therapies in Traditional Chinese Medicine[J]. Shi Yong Zhong Yi Yao Za Zhi, 2020, 36(1): 132-133.

Wang W, Shi LB, Zhang ML, et al. Effect of postoperative chemotherapy combined with Huaier granule on breast cancer and its effect on some markers[J]. Xi Bu Yi Xue, 2019, 31(1): 113-117.

Liu YC, Lin LQ, Zhang XB, et al. Xuefu Zhuyu decoction decreases the risk of bleeding induced by different antithrombotic drugs[J]. Zhongguo Xin Yao Za Zhi, 2024, 33(21): 2283-2289.

Li HX, Yang B, Ma CQ. Analysis of the therapeutic effect of negative pressure sealing drainage combined with Huang-lian-jie-du decoction irrigation in the treatment of diabetic foot with damp-heat toxicity syndrome[J]. Shi Yong Yi Yuan Lin Chuang Za Zhi, 2025, 22(4): 153-158.

Martínez-Zamudio RI, Robinson L, Roux PF, et al . SnapShot: Cellular Senescence Pathways[J ] . Cell, 2017, 170(4): 816-816. e1.

Expert Committee of Integrated Chinese and Western Medicine, CSCO. Expert consensus on the diagnosis and treatment of integrated Chinese and Western medicine for myelosuppression caused by antitumor drugs[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2021, 26(11): 1020-1027.

Clinical Chemotherapy Committee for Tumors, China Anti-Cancer Association. Expert Consensus on Out-of-hospital Management of Myelosuppression Related to Tumor Treatment[J]. Zhonghua Yi Xue Za Zhi, 2025, 105(11): 793-804.

Tumor Supportive Rehabilitation Therapy Group, Oncology Branch, Chinese Medical Association. Clinical practice guidelines for cancer-related fatigue in China (2021 edition)[J]. Zhongguo Ai Zheng Za Zhi, 2021, 31(9): 852-872.

Deng JW, Luo QR, Zhu HW, et al. Correlation analysis of WT1, BCR-ABL genes with IL-6, VEGF, PC and PS in myeloproliferative neoplasms[J]. Chongqing Yi Xue, 2025, 54(6): 1319-1322.

Romero D. Gastrointestinal cancer: Establishing a family tree[J]. Nat Rev Clin Oncol, 2017, 14(9): 524-525.

Fan XH, Jiao GS, Niu Y, et al. A case report of severe thrombocytopenia with venous thrombosis caused by bevacizumab[J]. Zhongguo Lin Chuang Yao Xue Za Zhi, 2025, 34(4): 312-314.

Li XY, Zhang HB, Yang FY, et al. Analysis of the characteristics of platelet changes and influencing factors after transcatheter aortic valve implantation[J]. Zhongguo Xiong Xin Xue Guan Wai Ke Lin Chuang Za Zhi, 2024, 31(6): 832-837.

Chinese Society of Clinical Oncology, China Anti-Cancer Association; Chinese Society of Supportive Oncology, China Anti-Cancer Association. Consensus on clinical diagnosis, treatment, and prevention of chemotherapy-induced neutropenia in China (2023 edition)[J]. Zhonghua Zhong Liu Za Zhi, 2023, 45(7): 575-583.

Thrombosis and Hemostasis Group, Hematology Branch, Chinese Medical Association. Chinese expert consensus on the clinical application of recombinant human thrombopoiein and thrombopoiein receptor agonist (2023)[J] Zhonghua Xue Ye Xue Za Zhi, 2023, 44(7): 535-542.

Du J, Zhang FK. Advances on thrombopoietin receptor agonist in severe aplastic anemia[J]. Zhonghua Xue Ye Xue Za Zhi, 2017, 38(9): 813-816.

Liu XY, Shi Y, Chao X, et al. Meta-Analysis on Clinical Efficacy and Safety of Kanglaite Injection on Primary Liver Cancer[J]. Zhongguo Yi Yuan Yong Yao Ping Jia Yu Fen Xi, 2025, 25(7): 851-855, 860.